ModerateHMG-CoA reductase inhibitors (statins)×Class III antiarrhythmic
Updated · Methodology
Mechanism
Dronedarone blocks CYP3A4 – a partial atorvastatin metabolic route. Atorvastatin plasma levels rise 2-fold, raising myalgia risk.
Symptoms
Pain and weakness in large muscle groups (thighs, shoulders, calves), dark urine, elevated creatine kinase. Symptoms usually appear 2–6 weeks after starting the combination.
Management
Cap atorvastatin at 20 mg/day when combined. If LDL targets are missed, switch to pravastatin or rosuvastatin (no CYP3A4 dependence).
Check the full regimen, not just this pair
Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.
Summary of a multi-drug list →
Medicine list: everything you take in one place →
Sources
- FDA: Multaq (dronedarone) prescribing information (2017)– ; DailyMed setid 7fa41601-7fb5-4155-8e50-2ae903f0d2d6
- AEMPS: Ficha técnica: Dronedarona (nº registro 84320), sección 4.5 (2025)– AEMPS, CIMA, nº registro 84320, revisión 10/2025, sección 4.5